Top

Published in:

01-10-2012 | Original Communication

Early biomarkers for post-stroke cognitive impairment

Authors: Lai Qian, Lidong Ding, Liqun Cheng, Xiaolei Zhu, Hui Zhao, Jiali Jin, Dening Guan, Bing Zhang, Xuemei Chen, Yun Xu

Published in: Journal of Neurology | Issue 10/2012

Abstract

The aim of this study was to investigate whether some biomarkers could predict cognitive impairment after stroke. One hundred fifty-two first-ever stroke patients were recruited within 6–72 h after the onset of symptoms. Blood was drawn within 1 h after admission for determining biomarkers. Cognitive function was assayed 2 weeks after stroke. The patients were divided into four groups: stroke, vascular cognitive impairment with no dementia (VCIND), vascular dementia (VaD), and mixed dementia (MD). Forty healthy subjects were used as controls. The results indicated that lower soluble receptor levels for advanced glycation end products (sRAGE) and higher β-secretase enzyme (BACE1) and neprilysin (NEP) levels were found in the VCIND, VaD, and MD groups. In addition, the percentages of ε3/ε4 genotypes and ε4 alleles in the VCIND, VaD, and MD groups were higher than in the stroke group. Correlation analysis determined that sRAGE, BACE1, and NEP were significantly related to the results of neuropsychological assessments. Logistic regression analysis, however, suggested that only sRAGE and BACE1 changed ahead of cognitive impairment after stroke. In conclusion, only BACE1 and sRAGE, not NEP or APOE genotypes, may be biomarkers diagnosing post-stroke cognitive impairment.

Andin U, Gustafson L, Passant U, Brun A (2005) A clinico-pathological study of heart and brain lesions in vascular dementia. Dement Geriatr Cogn Disord 19:222–228PubMedCrossRef

Armstrong RA (2008) The interface between Alzheimer’s disease, normal aging, and related disorders. Curr Aging Sci 1:122–132PubMedCrossRef

Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, Pondal M, Vivancos J, Del Ser T (2000) Poststroke dementia: clinical features and risk factors. Stroke 31:1494–1501PubMedCrossRef

Coulson DT, Beyer N, Quinn JG, Brockbank S, Hellemans J, Irvine GB, Ravid R, Johnston JA (2010) BACE1 mRNA expression in Alzheimer’s disease postmortem brain tissue. J Alzheimers Dis 22:1111–1122PubMed

Davidson Y, Gibbons L, Purandare N, Byrne J, Hardicre J, Wren J, Payton A, Pendleton N, Horan M, Burns A, Mann DM (2006) Apolipoprotein E epsilon4 allele frequency in vascular dementia. Dement Geriatr Cogn Disord 22:15–19PubMedCrossRef

Decourt B, Sabbagh MN (2011) BACE1 as a potential biomarker for Alzheimer’s disease. J Alzheimers Dis 24(Suppl 2):53–59PubMed

Dorfman VB, Pasquini L, Riudavets M, Lopez-Costa JJ, Villegas A, Troncoso JC, Lopera F, Castano EM, Morelli L (2010) Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer’s disease. Neurobiol Aging 31:1743–1757PubMedCrossRef

Emanuele E, D’Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, Bernardi L, Maletta R, Bruni AC, Geroldi D (2005) Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 62:1734–1736PubMedCrossRef

Erkinjuntti T (2002) Diagnosis and management of vascular cognitive impairment and dementia. J Neural Transm Suppl:91–109

10.

Jaillard A, Grand S, Le Bas JF, Hommel M (2010) Predicting cognitive dysfunctioning in nondemented patients early after stroke. Cerebrovasc Dis 29:415–423PubMedCrossRef

11.

Jin YP, Di Legge S, Ostbye T, Feightner JW, Hachinski V (2006) The reciprocal risks of stroke and cognitive impairment in an elderly population. Alzheimers Dement 2:171–178PubMedCrossRef

12.

Jin YP, Ostbye T, Feightner JW, Di Legge S, Hachinski V (2008) Joint effect of stroke and APOE 4 on dementia risk: the Canadian Study of Health and Aging. Neurology 70:9–16PubMedCrossRef

13.

Kalaria RN (2003) Comparison between Alzheimer’s disease and vascular dementia: implications for treatment. Neurol Res 25:661–664PubMedCrossRef

14.

Kamboh MI (2004) Molecular genetics of late-onset Alzheimer’s disease. Ann Hum Genet 68:381–404PubMedCrossRef

15.

Lewis H, Beher D, Cookson N, Oakley A, Piggott M, Morris CM, Jaros E, Perry R, Ince P, Kenny RA, Ballard CG, Shearman MS, Kalaria RN (2006) Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol 32:103–118PubMedCrossRef

16.

Leys D, Henon H, Mackowiak-Cordoliani MA, Pasquier F (2005) Poststroke dementia. Lancet Neurol 4:752–759PubMedCrossRef

17.

Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J (2000) Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A 97:1456–1460PubMedCrossRef

18.

Low LF, Yap MH, Brodaty H (2010) Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review. Neurosci Biobehav Rev 34:408–437PubMedCrossRef

19.

Luchsinger JA, Mayeux R (2004) Cardiovascular risk factors and Alzheimer’s disease. Curr Atheroscler Rep 6:261–266PubMedCrossRef

20.

Maetzler W, Stoycheva V, Schmid B, Schulte C, Hauser AK, Brockmann K, Melms A, Gasser T, Berg D (2010) Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-beta42 levels in Lewy body disease. J Alzheimers Dis 22:933–938PubMed

21.

Moorhouse P, Song X, Rockwood K, Black S, Kertesz A, Gauthier S, Feldman H (2010) Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. J Neurol Sci 288:142–146PubMedCrossRef

22.

Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, Schade RF (2004) Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 25:1023–1032PubMedCrossRef

23.

O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST (2003) Vascular cognitive impairment. Lancet Neurol 2:89–98PubMedCrossRef

24.

Park IH, Yeon SI, Youn JH, Choi JE, Sasaki N, Choi IH, Shin JS (2004) Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 40:1203–1211PubMedCrossRef

25.

Pull CB (1995) [Dsm-Iv]. Encephale 21 Spec No 5:15–20

26.

Rippon GA, Tang MX, Lee JH, Lantigua R, Medrano M, Mayeux R (2006) Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement. Neurology 66:35–40PubMedCrossRef

27.

Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A et al (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250–260PubMedCrossRef

28.

Sun ZZ, Chen ZB, Jiang H, Li LL, Li EG, Xu Y (2009) Alteration of Abeta metabolism-related molecules in predementia induced by AlCl3 and d-galactose. Age (Dordr) 31:277–284CrossRef

29.

Vardy ER, Catto AJ, Hooper NM (2005) Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer’s disease. Trends Mol Med 11:464–472PubMedCrossRef

30.

Vassar R (2004) BACE1: the beta-secretase enzyme in Alzheimer’s disease. J Mol Neurosci 23:105–114PubMedCrossRef

31.

Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ, Blennow K (2008) Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 65:1102–1107PubMedCrossRef

32.

Zhao QL, Zhou Y, Wang YL, Dong KH, Wang YJ (2010) A new diagnostic algorithm for vascular cognitive impairment: the proposed criteria and evaluation of its reliability and validity. Chin Med J (Engl) 123:311–319

33.

Zivelin A, Rosenberg N, Peretz H, Amit Y, Kornbrot N, Seligsohn U (1997) Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem 43:1657–1659PubMed

Title: Early biomarkers for post-stroke cognitive impairment
Authors: Lai Qian
Lidong Ding
Liqun Cheng
Xiaolei Zhu
Hui Zhao
Jiali Jin
Dening Guan
Bing Zhang
Xuemei Chen
Yun Xu
Publication date: 01-10-2012
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 10/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-012-6465-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Early biomarkers for post-stroke cognitive impairment

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2012

Comparison of clinical characteristics between familial and non-familial early onset Alzheimer’s disease

Correlates of tumor development in patients with myotonic dystrophy

Management of status epilepticus

POLG and PEO1 (Twinkle) mutations are infrequent in PSP-like atypical parkinsonism: a preliminary screening study

Lower motor neuron disease caused by a novel FUS/TLS gene frameshift mutation

Breastfeeding and multiple sclerosis relapses: a meta-analysis